Papers for

vaccine developers

Papers whose findings have a practical use for this group, as judged from the abstract. Open a paper to read what it means in practice.

ImmuneAgent AI system speeds antibody discovery across viruses

Multimodal reasoning for broadly neutralizing antibody discovery from label-free human B cell repertoires across virus families

Abstract: Discovering broadly neutralizing antibodies (bnAbs) from human natural immune repertoires remains a fundamental challenge in immunology, hindered by: the extreme rarity of bnAb, incomplete understanding of their cellular origins across pathogens, and the inability of existing computational tools to generalize across emerging viral threats. Here we present ImmuneAgent, a closed-loop AI system that integrates multimodal reasoning with continual meta-learning and wet-lab feedback to overcome these barriers. Applied to screen the natural BCR repertoires from vaccinated or infected cohorts, the system achieves a ~55% neutralization antibody discovery rate (60 of 110 cloned candidates) and a ~11% bnAb yield (12 of 110), substantially outperforming a state-of-the-art sequence-based neutralization predictor or cofolding models evaluated at the same cloning budget. Five ImmuneAgent-discovered antibodies conferred 100% in vivo protection against lethal influenza challenge, comparable to the clinical-stage therapeutic MEDI8852. The system recovered the cellular and structural determinants of bnAb activity and identified FCRL5+CD27+ atypical memory B cells as a conserved bnAb reservoir and hydrophobic interface enrichment as a cross-viral structural signature, which generalized to unseen antigens, discovering human metapneumovirus (hMPV) cross-neutralizing and human papillomavirus (HPV)-neutralizing antibodies without antigen-specific sorting. These results validate that ImmuneAgent is a generalizable framework for rapid therapeutic antibody discovery against emerging viral threats.

Fri 2 OctArtificial IntelligenceComputational Engineering, Finance, and Science
The gist
Finding rare antibodies that can fight many viruses is very hard because they are so rare and hard to identify. The authors created ImmuneAgent, an AI system that learns continuously and uses lab feedback to find these rare antibodies in human immune cells. It found many effective antibodies, some protecting mice from deadly flu, and even worked on viruses it hadn’t seen before. This system could help quickly find new treatments for emerging viral infections.
Open → 2610.03160v1